Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A

Haemophilia

Volumn 13, Issue 2, 2007, Pages 149-155

  Chalmers, Elizabeth A ^a   Brown, S A ^b   Keeling, D ^c   Liesner, R ^d   Richards, M ^e   Stirling, D ^f   Thomas, A ^g   Vidler, V ^h   Williams, M D ⁱ   Young, D ^a  

^a ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^e ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^f ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^g ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^h SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

ⁱ BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Children; Factor VIII; Haemophilia; Inhibitor

Indexed keywords

BLOOD CLOTTING FACTOR 8 ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CHROMOSOME INVERSION; COHORT ANALYSIS; DISEASE SEVERITY; DRUG DOSAGE FORM COMPARISON; EARLY CHILDHOOD INTERVENTION; ENVIRONMENTAL FACTOR; GENE DELETION; GENE INSERTION; HEMOPHILIA A; HEREDITY; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MISSENSE MUTATION; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT;

ADOLESCENT; AGE OF ONSET; BLOOD COAGULATION FACTOR INHIBITORS; CHILD; CHILD, PRESCHOOL; FACTOR VIII; HEMOPHILIA A; HUMANS; INFANT; INFANT, NEWBORN; PEDIGREE; RISK FACTORS;

EID: 33846922841     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2006.01418.x     Document Type: Article

References (22)

1. Key NS. Inhibitors in congenital coagulation disorders. Br J Haematol 2004; 127: 379-91.
2. Bohn RL, Aledort LM, Putnam KG, Ewenstein BM, Mogun H, Avorn J. The economic impact of factor VIII inhibitors in patients with haemophilia. Haemophilia 2004; 10: 63-8.
3. White GC, Kempton CL, Grimsley B, Nielson B, Roberts HR. Cellular immune responses in haemophilia: Why do inhibitors develop in some, but not all hemophiliacs. J Thromb Haemost 2005; 3: 1676-81.
4. Goodeve A. The incidence of inhibitor development according to specific mutations - and treatment? Blood Coagul Fibrinolysis 2003; 4 (Suppl. 1): S17-21.
5. Van den Berg HM, Rosendaal G, Voorberg J, Mauser-Bunschoten EP. Inhibitor development in a multitransfused patient with severe haemophilia A. Thromb Haemost 1999; 82: 151-2.
6. Sharathkumar A, Lillicrap D, Blanchette VS et al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. Thromb Haemost 2003; 1: 1228-36.
7. Goudemand J, Rothschild C, Demiguel V et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 46-51.
8. Lorenzo JI, Lopez A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe haemophilia: The importance of patient age. Br J Haematol 2001; 113: 600-3.
9. Van der Bom JG, Mauser-Bunschoten P, Fischer K, van den Berg HM. Age at first treatment and immune tolerance to factor VIII in severe hemophilia. Thromb Haemost 2003; 98: 475-9.
10. Santagostino E, Mancuso ME, Rocino A et al. Environmental risk factors for inhibitor development in children with haemophilia A: A case-control study. Br J Haematol 2005; 130: 422-7.
11. Rivard GE, Lillicrap D, Poon MC et al. Can activated recombinant factor VII be used to postpone the exposure of infants to factor VIII until after 2years of age ? Haemophilia 2005; 11: 335-9.
12. Buchanan GR. Factor concentrate prophylaxis for neonates with hemophilia. J Paediatr Hematol Oncol 1999; 21: 254-5.
13. Ljung R, Lindgren AC, Patrini P, Tengborn L. Normal vaginal delivery is recommended for hemophilia carrier gravidae. Acta Paediatr 1994; 83: 609-11.
14. Chambost H, Gaboulaud V, Coatmelec B, Rafowicz A, Schneider P, Calvez T. What factors influence the age at diagnosis of hemophilia? Results of a French cohort study. J Pediatr 2002; 141: 548-52.
15. Oldenburg J, Schroder J, Hermann Brackmann H, Muller-Reible C, Schwaab R, Tuddenham E. Environmental and genetic factors influencing inhibitor development. Semin Hematol 2004; 41: 82-8.
16. Aledort LM, DiMichele DM. Inhibitors occur more frequently in Africo-American and Latino haemophiliacs. Haemophilia 1998; 4: 68.
17. Astermark J, Berntorp E, White GC, Kroner BL, and the MIBS Study Group. The Malmo International Brother Study (MIBS): Further support for genetic predisposition to inhibitor development in haemophilia patients. Haemophilia 2001; 7: 267-72.
18. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: A systematic review. Haemophilia 2003; 9: 418-35.
19. Aledort LM. Is the incidence and prevalence of inhibitors greater with recombinant products? Yes. J Thromb Haemost 2004; 2: 861-2.
20. Lusher JM. Is the incidence and prevalence of inhibitors greater with recombinant products? No. J Thromb Haemost 2004; 2: 863-5.
21. Tuddenham EGD. Factor VIII: Purer is not necessarily better. Blood 2006; 107: 4-5.
22. Gouw SC. The concerted action on neutralizing antibodies in severe haemophilia A (Canal Study): Preliminary findings. J Thromb Haemost 2005; 3 (Suppl. 1): OR093.